Makarov et al reported update Partin tables based on data form 2000 to 2005. The authors are from the Johns Hopkins University.
Patient selection: male with clinically localized prostate cancer
Parameters:
(1) T code from T1c to T2b
(2) serum PSA in ng/mL
(3) Gleason score
OC = organ confined
ECE = extracapsular extension
SV = seminal vesicle involvement
LN = lymph node metastases
T Code |
PSA |
GS |
OC |
ECE |
SV+ |
LN+ |
T1c |
0 to 2.5 |
5 or 6 |
93 |
6 |
0 |
0 |
|
|
3+4 |
82 |
14 |
2 |
2 |
|
|
4+3 |
73 |
20 |
2 |
4 |
|
|
8 to 10 |
77 |
16 |
3 |
3 |
|
2.6 to 4.0 |
5 or 6 |
88 |
11 |
1 |
0 |
|
|
3+4 |
72 |
23 |
4 |
1 |
|
|
4+3 |
61 |
33 |
5 |
1 |
|
|
8 to 10 |
66 |
26 |
7 |
1 |
|
4.1 to 6 |
5 or 6 |
83 |
16 |
1 |
0 |
|
|
3+4 |
63 |
30 |
6 |
2 |
|
|
4+3 |
51 |
40 |
7 |
3 |
|
|
8 to 10 |
55 |
32 |
10 |
3 |
|
6.1 to 10 |
5 or 6 |
81 |
18 |
1 |
0 |
|
|
3+4 |
59 |
32 |
8 |
1 |
|
|
4+3 |
47 |
42 |
8 |
3 |
|
|
8 to 10 |
51 |
34 |
12 |
3 |
|
> 10 |
5 or 6 |
70 |
27 |
2 |
1 |
|
|
3+4 |
42 |
40 |
12 |
6 |
|
|
4+3 |
30 |
48 |
11 |
10 |
|
|
8 to 10 |
34 |
39 |
17 |
9 |
T2a |
0 to 2.5 |
5 or 6 |
88 |
12 |
0 |
0 |
|
|
3+4 |
70 |
24 |
2 |
3 |
|
|
4+3 |
58 |
32 |
3 |
7 |
|
|
8 to 10 |
63 |
26 |
4 |
6 |
|
2.6 to 4.0 |
5 or 6 |
79 |
20 |
1 |
0 |
|
|
3+4 |
57 |
37 |
5 |
1 |
|
|
4+3 |
45 |
48 |
5 |
2 |
|
|
8 to 10 |
50 |
40 |
8 |
2 |
|
4.1 to 6 |
5 or 6 |
71 |
27 |
1 |
0 |
|
|
3+4 |
47 |
44 |
7 |
2 |
|
|
4+3 |
34 |
54 |
7 |
5 |
|
|
8 to 10 |
39 |
46 |
11 |
4 |
|
6.1 to 10 |
5 or 6 |
68 |
29 |
2 |
0 |
|
|
3+4 |
43 |
46 |
9 |
2 |
|
|
4+3 |
31 |
56 |
9 |
4 |
|
|
8 to 10 |
36 |
47 |
13 |
4 |
|
> 10 |
5 or 6 |
54 |
41 |
3 |
1 |
|
|
3+4 |
28 |
52 |
12 |
7 |
|
|
4+3 |
18 |
57 |
11 |
13 |
|
|
8 to 10 |
21 |
49 |
17 |
12 |
T2b |
0 to 2.5 |
5 or 6 |
84 |
14 |
1 |
1 |
|
|
3+4 |
59 |
24 |
6 |
10 |
|
|
4+3 |
44 |
29 |
6 |
19 |
|
|
8 to 10 |
49 |
24 |
8 |
17 |
|
2.6 to 4.0 |
5 or 6 |
74 |
23 |
2 |
0 |
|
|
3+4 |
47 |
37 |
13 |
3 |
|
|
4+3 |
36 |
46 |
13 |
5 |
|
|
8 to 10 |
39 |
37 |
19 |
4 |
|
4.1 to 6 |
5 or 6 |
66 |
30 |
4 |
1 |
|
|
3+4 |
36 |
41 |
16 |
7 |
|
|
4+3 |
25 |
47 |
15 |
13 |
|
|
8 to 10 |
27 |
38 |
22 |
11 |
|
6.1 to 10 |
5 or 6 |
62 |
32 |
5 |
1 |
|
|
3+4 |
32 |
41 |
20 |
6 |
|
|
4+3 |
22 |
47 |
19 |
11 |
|
|
8 to 10 |
24 |
38 |
27 |
10 |
|
> 10 |
5 or 6 |
46 |
41 |
7 |
5 |
|
|
3+4 |
18 |
40 |
23 |
18 |
|
|
4+3 |
11 |
40 |
19 |
29 |
|
|
8 to 10 |
12 |
33 |
28 |
26 |
Specialty: Hematology Oncology